-
Something wrong with this record ?
Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid
M. Kaleta, E. Hényková, K. Menšíková, D. Friedecký, A. Kvasnička, K. Klíčová, D. Koníčková, M. Strnad, P. Kaňovský, O. Novák
Language English Country United States
Document type Journal Article
- MeSH
- Alzheimer Disease * diagnosis MeSH
- Biomarkers MeSH
- Kynurenine MeSH
- Humans MeSH
- Proteostasis Deficiencies * MeSH
- Serum MeSH
- Tauopathies * MeSH
- Tryptophan MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Some pathological conditions affecting the human body can also disrupt metabolic pathways and thus alter the overall metabolic profile. Knowledge of metabolic disturbances in specific diseases could thus enable the differential diagnosis of otherwise similar conditions. This work therefore aimed to comprehensively characterize changes in tryptophan metabolism in selected neurodegenerative diseases. Levels of 18 tryptophan-related neuroactive substances were determined by high throughput and sensitive ultrahigh-performance liquid chromatography-tandem mass spectrometry in time-linked blood serum and cerebrospinal fluid samples from 100 age-matched participants belonging to five cohorts: healthy volunteers (n = 21) and patients with Lewy body disease (Parkinson's disease and dementia with Lewy bodies; n = 31), four-repeat tauopathy (progressive supranuclear palsy and corticobasal syndrome; n = 10), multiple system atrophy (n = 13), and Alzheimer's disease (n = 25). Although these conditions have different pathologies and clinical symptoms, the discovery of new biomarkers is still important. The most statistically significant differences (with p-values of ≤0.05 to ≤0.0001) between the study cohorts were observed for three tryptophan metabolites: l-kynurenine in cerebrospinal fluid and 3-hydroxy-l-kynurenine and 5-hydroxy-l-tryptophan in blood serum. This led to the discovery of distinctive correlation patterns between the profiled cerebrospinal fluid and serum metabolites that could provide a basis for the differential diagnosis of neurodegenerative tauopathies and synucleinopathies. However, further large-scale studies are needed to determine the direct involvement of these metabolites in the studied neuropathologies, their response to medication, and their potential therapeutic relevance.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007191
- 003
- CZ-PrNML
- 005
- 20240423155759.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acschemneuro.3c00611 $2 doi
- 035 __
- $a (PubMed)38194490
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kaleta, Michal $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000308752912
- 245 10
- $a Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid / $c M. Kaleta, E. Hényková, K. Menšíková, D. Friedecký, A. Kvasnička, K. Klíčová, D. Koníčková, M. Strnad, P. Kaňovský, O. Novák
- 520 9_
- $a Some pathological conditions affecting the human body can also disrupt metabolic pathways and thus alter the overall metabolic profile. Knowledge of metabolic disturbances in specific diseases could thus enable the differential diagnosis of otherwise similar conditions. This work therefore aimed to comprehensively characterize changes in tryptophan metabolism in selected neurodegenerative diseases. Levels of 18 tryptophan-related neuroactive substances were determined by high throughput and sensitive ultrahigh-performance liquid chromatography-tandem mass spectrometry in time-linked blood serum and cerebrospinal fluid samples from 100 age-matched participants belonging to five cohorts: healthy volunteers (n = 21) and patients with Lewy body disease (Parkinson's disease and dementia with Lewy bodies; n = 31), four-repeat tauopathy (progressive supranuclear palsy and corticobasal syndrome; n = 10), multiple system atrophy (n = 13), and Alzheimer's disease (n = 25). Although these conditions have different pathologies and clinical symptoms, the discovery of new biomarkers is still important. The most statistically significant differences (with p-values of ≤0.05 to ≤0.0001) between the study cohorts were observed for three tryptophan metabolites: l-kynurenine in cerebrospinal fluid and 3-hydroxy-l-kynurenine and 5-hydroxy-l-tryptophan in blood serum. This led to the discovery of distinctive correlation patterns between the profiled cerebrospinal fluid and serum metabolites that could provide a basis for the differential diagnosis of neurodegenerative tauopathies and synucleinopathies. However, further large-scale studies are needed to determine the direct involvement of these metabolites in the studied neuropathologies, their response to medication, and their potential therapeutic relevance.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a tryptofan $7 D014364
- 650 _2
- $a kynurenin $7 D007737
- 650 _2
- $a sérum $7 D044967
- 650 12
- $a Alzheimerova nemoc $x diagnóza $7 D000544
- 650 12
- $a tauopatie $7 D024801
- 650 12
- $a poruchy proteostázy $7 D057165
- 650 _2
- $a biologické markery $7 D015415
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hényková, Eva $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000340337786
- 700 1_
- $a Menšíková, Kateřina $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Friedecký, David $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Zdravotníků 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000234489073 $7 xx0142900
- 700 1_
- $a Kvasnička, Aleš $u Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Zdravotníků 248/7, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000015973316X
- 700 1_
- $a Klíčová, Kateřina $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000275284146
- 700 1_
- $a Koníčková, Dorota $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000344460060
- 700 1_
- $a Strnad, Miroslav $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000022806794X
- 700 1_
- $a Kaňovský, Petr $u Department of Neurology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Novák, Ondřej $u Laboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences & Palacky University, Šlechtitelů 27, 783 71 Olomouc, Czech Republic $1 https://orcid.org/0000000334520154 $7 xx0120183
- 773 0_
- $w MED00193636 $t ACS chemical neuroscience $x 1948-7193 $g Roč. 15, č. 3 (2024), s. 582-592
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38194490 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155755 $b ABA008
- 999 __
- $a ok $b bmc $g 2081274 $s 1216958
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 15 $c 3 $d 582-592 $e 20240109 $i 1948-7193 $m ACS chemical neuroscience $n ACS Chem Neurosci $x MED00193636
- LZP __
- $a Pubmed-20240412